Adenoviral Gene Therapy Death Will Be Explored By NIH rDNA Committee
Executive Summary
Safety and efficacy of adenoviral vectors for therapeutic application will be examined at the Dec. 9-10 meeting of the NIH Recombinant DNA Advisory Committee. The action follows the death of a teenager enrolled in a gene therapy trial at the University of Pennsylvania Medical Center.
You may also be interested in...
Gene Transfer Trials Should Require Sequencing Of Small Vectors - Cmte.
FDA should require complete sequencing of gene transfer vectors up to 40 kilo bases in size before initiation of a Phase I gene transfer therapy clinical trial, the Biological Response Modifiers Advisory Committee recommended Nov. 16.
Gene Transfer Trials Should Require Sequencing Of Small Vectors - Cmte.
FDA should require complete sequencing of gene transfer vectors up to 40 kilo bases in size before initiation of a Phase I gene transfer therapy clinical trial, the Biological Response Modifiers Advisory Committee recommended Nov. 16.
Genzyme Purchase Of Cell Genesys Shows Confidence In Gene Therapy Future
Genzyme's $350 mil. acquisition of Cell Genesys represents a vote of confidence in gene therapy after concerns about the death of a clinical trial subject.